Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab

Eur J Cancer. 2018 Feb:90:146-148. doi: 10.1016/j.ejca.2017.11.008. Epub 2017 Dec 11.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Apocrine Glands / pathology
  • Humans
  • Male
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Sweat Gland Neoplasms / drug therapy*
  • Sweat Gland Neoplasms / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • pembrolizumab